PPGN POLYPEPTIDE GROUP AG

PolyPeptide publishes invitation to the annual General Meeting 2025

PolyPeptide Group / Key word(s): AGMEGM
PolyPeptide publishes invitation to the annual General Meeting 2025

18.03.2025 / 07:00 CET/CEST


Media release

PolyPeptide publishes invitation to the annual General Meeting 2025

Baar, 18 March 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fourth annual General Meeting, which will take place on 9 April 2025 at the Chollerhalle in Zug.

At PolyPeptide Group AG’s (the “Company”) fourth annual General Meeting, which will take place on 9 April 2025 at the Chollerhalle in Zug (the “AGM 2025”), five current members of the Board of Directors will stand for re-election. Beat In-Albon has decided not to stand for re-election as a member of the Board of Directors. The Board of Directors thanks Mr. In-Albon for his dedicated service and valuable contributions. Peter Wilden is proposed for re-election as Chair of the Board of Directors, and Philippe Weber and Peter Wilden as members of the Remuneration and Nomination Committee. As announced on 11 March 2025, the Board of Directors further proposes Jo LeCouilliard for election as new independent member of the Board of Directors, and upon election it is expected that Ms. LeCouilliard will join the Audit and Risk Committee.

The Board of Directors further proposes to the AGM 2025 the introduction of a capital band in a new art. 3a of the Company's Articles of Association and the introduction of a conditional share capital for financing purposes and finance instruments in a new art. 3c of the Company's Articles of Association. The capital band shall provide the Board of Directors with the flexibility to increase the Company’s share capital within a predefined range, thereby enhancing the Company's financial and strategic agility. The conditional share capital shall increase the Company's financing and refinancing flexibility.

Further proposals include, among others, the re-election of the Statutory Auditors and the Independent Proxy as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. The shareholders will also be asked to approve the Management Report, Statutory Financial Statements, Consolidated Financial Statements and the report on non-financial matters, in each case, for the financial year 2024 as well as the Remuneration Report 2024 in separate consultative vote.

The invitation to the AGM 2025 with the detailed proposals and explanations can be found on the Company’s .

Contact

PolyPeptide Group AG

Michael Stäheli

Head of Investor Relations & Corporate Communications

T:

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical through to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with a large exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.

For more information, please visit .  

@PolyPeptide – follow us on

Disclaimer

This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.



End of Media Release


Language: English
Company: PolyPeptide Group
Neuhofstrasse 24
6340 Baar
Switzerland
Phone:
E-mail:
Internet:
ISIN: CH1110760852
Valor: 111076085
Listed: SIX Swiss Exchange
EQS News ID: 2101938

 
End of News EQS News Service

2101938  18.03.2025 CET/CEST

EN
18/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on POLYPEPTIDE GROUP AG

 PRESS RELEASE

PolyPeptide publiziert Einladung zur ordentlichen Generalversammlung 2...

PolyPeptide Group / Schlagwort(e): Generalversammlung PolyPeptide publiziert Einladung zur ordentlichen Generalversammlung 2025 18.03.2025 / 07:00 CET/CEST Medienmitteilung PolyPeptide publiziert Einladung zur ordentlichen Generalversammlung 2025 Baar, 18. März 2025 – PolyPeptide Group AG (SIX: PPGN), eine spezialisierte globale CDMO für peptidbasierte aktive pharmazeutische Wirkstoffe, hat heute die Einladung zur vierten ordentlichen Generalversammlung publiziert, die am 9. April 2025 in der Chollerhalle in Zug stattfinden wird. An PolyPeptide Group AG’s (die "Gesellsch...

 PRESS RELEASE

PolyPeptide publishes invitation to the annual General Meeting 2025

PolyPeptide Group / Key word(s): AGMEGM PolyPeptide publishes invitation to the annual General Meeting 2025 18.03.2025 / 07:00 CET/CEST Media release PolyPeptide publishes invitation to the annual General Meeting 2025 Baar, 18 March 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fourth annual General Meeting, which will take place on 9 April 2025 at the Chollerhalle in Zug. At PolyPeptide Group AG’s (the “Company”) fourth annual General Meeting, which will take place...

 PRESS RELEASE

Doubling of production capacity at the manufacturing site in Malmö

PolyPeptide Group / Key word(s): Expansion Doubling of production capacity at the manufacturing site in Malmö 08.01.2025 / 07:00 CET/CEST Media release Doubling of production capacity at the manufacturing site in Malmö Baar, 8 January 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the planned doubling of solid-phase peptide synthesis (SPPS) capacity at its manufacturing site in Malmö, Sweden. The construction work is already underway, along with the supporting infrastructure, including a tan...

 PRESS RELEASE

Verdoppelung der Produktionskapazität am Standort Malmö

PolyPeptide Group / Schlagwort(e): Expansion Verdoppelung der Produktionskapazität am Standort Malmö 08.01.2025 / 07:00 CET/CEST Medienmitteilung Verdoppelung der Produktionskapazität am Standort Malmö Baar, 8. Januar 2025 – PolyPeptide Group AG (SIX: PPGN), ein spezialisierter globaler CDMO für peptidbasierte aktive pharmazeutische Wirkstoffe, kündigt die geplante Verdoppelung der Kapazität für die Festphasenpeptidsynthese (SPPS) am Produktionsstandort Malmö, Schweden, an. Die Konstruktionsarbeiten sind bereits im Gang, zusammen mit der unterstützenden Infrastruktur, in...

 PRESS RELEASE

Large-scale SPPS capacity in Braine-l’Alleud starts production

PolyPeptide Group / Key word(s): Miscellaneous Large-scale SPPS capacity in Braine-l’Alleud starts production 16.12.2024 / 07:00 CET/CEST Media release Large-scale SPPS capacity in Braine-l’Alleud starts production Baar, 16 December 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the start of production with the new large-scale SPPS capacity at its manufacturing site in Braine-l’Alleud, Belgium. Following the completion of construction and thorough testing, PolyPeptide commissioned its new solid...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch